Boston Scientific Adds Dr. Cheryl Pegus to Board

Boston Scientific Corporation (NYSE: BSX) has elected Dr. Cheryl Pegus to its board of directors, effective immediately. Dr. Pegus brings with her more than 25 years of clinical and business leadership experience, having served in various executive roles at notable organizations such as Morgan Health, Walmart, Cambia Health Solutions, and Walgreens. She began her career as a cardiologist in private practice and has held positions at Pfizer, Aetna, and Johnson & Johnson.

Dr. Pegus is also recognized for her board and co-founder roles in organizations dedicated to improving cardiovascular health and advancing the careers of women and underrepresented minorities in the field. She holds multiple degrees, including a B.A. from Brandeis University, an M.D. from Weill Cornell Medical College, and an M.P.H. from Columbia University Mailman School of Public Health.

Boston Scientific Corporation, a global medical technology leader, aims to advance science for life by providing a range of high-performance solutions to address unmet patient needs and reduce healthcare costs. Its portfolio includes devices and therapies for complex cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases and conditions.

The appointment of Dr. Pegus to the board of directors reflects the company's commitment to incorporating diverse and experienced perspectives in its governance. Her election underscores Boston Scientific's dedication to driving innovation and improving healthcare outcomes for patients worldwide. Following these announcements, the company's shares moved -0.6%, and are now trading at a price of $73.69. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.